CClinicalTrials.gg
CompletedNCT04552301Updated Sep 19, 2024Results posted

Assessing Inflammatory and Behavioral Pathways Linking PTSD to Increased Asthma Morbidity in WTC Workers

An interventional study of Cognitive Processing Therapy and Psychotherapy in Asthma and PTSD, sponsored by Icahn School of Medicine at Mount Sinai. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
361
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Asthma and post-traumatic stress disorder (PTSD) are the most common conditions in World Trade Center (WTC) rescue and recovery workers. In this study, the study team will evaluate the interplay of biological and behavioral mechanisms explaining the relationship of PTSD with increase asthma morbidity and adapt and pilot test a novel intervention to improve outcomes of WTC workers.

Read the detailed description

SIGINIFICANCE: Importance of the Problem: Multiple studies have shown a high prevalence of asthma in WTC rescue and recovery workers, local residents, and passersby. Using data from the National Health Interview Survey (NHIS), the researchers found that WTC workers have twice the risk of asthma compared to the general United States (US) population. Data from the WTCHP shows a 28% cumulative incidence of asthma 9 years after September 11, 2001 among WTC workers. These studies show that asthma is the most prevalent respiratory condition among WTC rescue and recovery workers.

WTC workers with asthma include individuals with prior history of the disease and new cases of irritant-induced asthma. Many workers with preexistent asthma developed worsening symptoms after WTC-related exposures (WTC-exacerbated asthma). Other workers developed new asthma symptoms without latency during or after WTC exposure and were diagnosed with irritant-induced asthma. Multiple cases of new onset asthma among WTC workers have been reported in the years following exposure to the WTC site; characterization of these cases has been more difficult. Despite this potential heterogeneity, these conditions are frequently grouped in clinical practice as WTC-related asthma and managed similarly.

Studies found substantial burden of asthma morbidity in WTC workers and exposed community members, with reports of poorly-controlled in 34% and very poorly-controlled symptoms in 35% of exposed individuals. Increased risk of emergency department (ED) visits and hospitalizations as well as poor quality of life in WTC workers with asthma have been reported, showing a major impact on health.

Scientific Premise of Project: PTSD is Associated with Increased Asthma Morbidity in WTC Workers: Prevalence of psychological symptoms in WTC-exposed populations is high; with PTSD reported as the most common (\~30%) mental health condition. Studies have also found high rates (25-35%) of PTSD comorbidity in WTC workers with asthma. Mental health conditions and PTSD in particular, have been associated with increased asthma morbidity. The researchers found that WTC workers with PTSD had worse asthma control, increased healthcare use, and poorer quality of life (see preliminary data). Similarly, a study of WTC workers indicated that severity of PTSD symptoms predicted new onset and worsening of asthma. Data from studies in the general population have also shown that PTSD is associated with higher asthma morbidity. In summary, studies have documented a high level of overlap between asthma and PTSD in WTC workers and other exposed populations and have documented that PTSD is a major contributor to increased asthma morbidity. However, the underlying mechanisms explaining this relationship remain unknown.

Potential Biological Pathways Linking PTSD and Asthma Morbidity: The impact of PTSD extends to multiple organ systems as a consequence of changes in the hypothalamic-pituitary axis, the autonomic nervous system, and the immune system.These PTSD-associated systemic alterations may impact asthma morbidity. PTSD is associated with a basal low-grade systemic inflammation, in particular, increased plasma levels of pro-inflammatory cytokines such as interleukin (IL)-1α, IL-2, IL-6, tumor necrosis factor-alpha (TNF-α and decreased IL-4, IL-5 ("Th2-cytokines"). Airway inflammation, a central feature of asthma, may be modulated by enhanced systemic inflammation as that observed in PTSD. Major asthma endotypes, which describe asthma subtypes based on inflammatory mechanisms, include allergic, intrinsic (non-atopic), and noneosinophilic asthma. Allergic asthma is characterized by airway eosinophilia driven by TH2-dominant inflammation. Noneosinophilic asthma is characterized by airway neutrophilia has been associated with refractory disease, severe exacerbations, and increased risk of intubation. Key cytokines driving neutrophilic asthma include IL-1β, IL-6 and IL-17, which are elevated in patients with PTSD.51 IL-6 directs and stabilized T-cells towards a Th17 subset, which can then recruit and activate of neutrophils. Therefore, systemic inflammatory changes associated with PTSD, may worsen asthma outcomes by driving a neutrophilic asthma phenotype. Identification of the biological pathways underlying worse asthma in patients with comorbid PTSD has important implications for disease management including indications for inhaled corticosteroids (ICS) and new biological drugs and may offer new alternative targets for therapy.

Symptom Perception in Asthma Patients with Comorbid PTSD: Effective asthma SMB requires the patient to recognize and respond (use of rescue medication, contact physician, etc.) to their symptoms. Self-monitoring of symptoms is also key for assessing response to treatment and thus, developing effective self-regulatory mechanisms (i.e., ICS linked to improved symptoms; see theoretical framework). Unfortunately, the symptoms that asthma patients experience do not always align with objective measures of their airway obstruction. Experiments have identified 3 asthma symptom perception phenotypes that have important clinical implications: symptom under-perceivers, normal perceivers, and over-perceivers. Prior studies have shown a strong relationship between misperception of symptoms and increased asthma morbidity.

While PTSD is associated with increased objective and subjective asthma morbidity markers, the associations with subjective measures are stronger. The researchers found that PTSD had strong associations with disease control measures and quality of life in WTC workers with asthma. However, the association with FEV1 was weaker (see preliminary data). Other studies had similar findings. These data strongly suggest that over-perception of symptoms may be prevalent among WTC workers with PTSD and may contribute to increased asthma morbidity and complicate SMB. The hypotheses for over-perception of symptoms among WTC workers with PTSD is based on Janssens's cognitive-affective model of symptom perception. A central factor in this model is negative affect common among patients with PTSD. Janssens's model89 proposes that negative affect will be linked with over-perception of symptoms via an associative learning mechanism. Because asthma exacerbations cause a negative affective state, an association between such a state and asthma symptoms develops in patients with PTSD. As a consequence, subsequent negative emotional states due to PTSD may results in the report of severe asthma symptoms in the presence of mild or no airway obstruction. The effect of negative affect is most pronounced on the affective component (i.e., unpleasantness dimension) of dyspnea. Thus, PTSD patients may perceive more asthma symptoms due to perceptions of unpleasant sensations of dyspnea.

PTSD is also characterized by a disruption in the ability to regulate emotions, which can lead to exaggerated emotional reactions to asthma-symptoms, in turn leading to symptom magnification. One relevant cognitive vulnerability factor common to PTSD and asthma is anxiety sensitivity, the tendency to catastrophically misinterpret the bodily sensations associated with anxious arousal (e.g., shortness of breath or chest pounding) as threatening. Anxiety sensitivity is more common among patients with asthma, strongly implicated in the experience of dyspnea, and associated with poor asthma control, and greater behavioral avoidance. Recent work by Dr. Gonzalez (Consultant) indicates that anxiety sensitivity, physical concerns in particular, plays a significant role in understanding the PTSD-asthma symptom link in WTC workers (see preliminary data).

Assessing Asthma Symptom Perception: Symptom perception is typically measured in laboratories by self-reported respiratory symptoms while inducing airway constriction with histamine or methacholine. However, this approach produces biased data because it generates anxiety and primes patients for certain reactions. In contrast, measurements in naturalistic settings (e.g., their home), as the researchers propose to do, is a validated method that reduces the emotional threat of the test environment and omits pharmacological techniques and devices that may generate anxiety.

PTSD May Negatively Impact Asthma SMB: Asthma self-management encompasses several complex behaviors such as adherence to controller medications, adequate inhaler technique, use of action plans, allergen avoidance, and avoiding tobacco exposure that are critical for adequate disease control. Adherence to controller medications in particular, is a factor that heavily influences the outcomes of asthmatics. Studies conducted in the general population and the preliminary data from WTC workers shown that only \~50% of patients with asthma adhere to controller therapy or other SMB.

Mental health conditions are associated with low adherence to chronic disease SMB. PTSD, in particular, has been strongly associated with low treatment adherence in multiple chronic diseases.With smoking being an important part of asthma self-management, it is of special concern that higher rates of smoking have been reported among WTC workers with PTSD. Thus, low adherence to SMB may mediate, in part, the association between PTSD and increased asthma morbidity. However, there is limited data regarding the relationship between PTSD and asthma SMB in the general population or among WTC workers, in particular.

Theoretical Framework: Pathways Mediating the Influence of PTSD on SMB: The researchers will use the Self-regulation Model (SRM) to guide the exploration of the relationship between PTSD and asthma SMB via illness beliefs, emotional representations and symptoms perception. According to the SRM, people with chronic illness, like asthma, compare their somatic sensations (i.e., symptoms) to their "normal" self, and interpret deviations from "normal" in relation to their mental model of their illness, which in turn guides their SMB. Appraisal of the efficacy of their actions (i.e., improved asthma control) serves as a feedback loop to reinforce or modify SMB. The SRM posits five domains of cognitive representations of illness: identity (disease labels), cause (etiology and triggers), timeline (chronicity), consequences (perceived impact), and control (extent to which an illness can be controlled). For example, if asthma patients accurately perceive their respiratory symptoms (identity) and believe asthma is persistent (timeline) they will engage in SMB. The SRM also predicts that patients will be adherent if they learn, via feedback loops, that their asthma medications can prevent symptoms (controllability). Emotional responses to asthma (i.e., worry, upset, or anxious) also influence SMB. The framework of the SRM is highly useful for identifying the modifiable beliefs and emotional mechanisms which underlie behaviors worth targeting for self-management support interventions. The researchers expect that PTSD may impact asthma SMB in several ways. WTC workers with PTSD may magnify asthma symptoms (identity) when they are actually experiencing negative emotions. Over-perception of symptoms could be a major barrier for internalizing positive feedback loops about medication effectiveness, leading to low adherence. WTC workers with PTSD and asthma may also misinterpret the causes of their asthma symptoms and thus, avoid situations that trigger the physical sensations they fear. Paradoxically, decreasing the frequency of PTSD symptoms via avoidance of perceived (not actual) asthma triggers may contribute to illness representations that focus more on this maladaptive avoidance, and less on SMB. Some patients view asthma as a chronic (timeline) inflammatory condition (cause), which requires adherence to daily ICS. Data from non-WTC asthma populations shows that patients with PTSD are more likely to view asthma as an acute, episodic disease.This 'acute' representation of asthma has been associated to low medication adherence. Patients with PTSD also tend to feel out of control (due to unexpected symptoms and catastrophic thoughts) and have lower self-efficacy, which has been linked to low ICS adherence. According to the SRM, emotional responses also influence SMB. As discussed above, patients with PTSD have emotional regulation difficulties; thus, strong negative emotional reactions to asthma may deplete WTC workers' self-regulatory resources managing emotions to the detriment of asthma SMB.SRM has also shown that medication beliefs strongly predict ICS adherence. Negative affect in workers with PTSD may extend to patients' beliefs about ICS (e.g., side effects, dependence, etc.) negatively influencing adherence. Moreover, patients with PTSD may avoid asthma medications and awareness of symptoms because these factors may serve as trauma cues or reminders of 9/11, triggering memories of their WTC traumatic experiences. Thus, this copying style (avoidance) may lead to low medication adherence.

Absence of Interventions Integrating PTSD and Asthma Management: Despite the strong link between asthma and PTSD in WTC workers, there are no interventions aimed at managing both conditions. Dr. Gonzalez is conducting a randomized clinical trial (RCT) to evaluate an integrative mind-body treatment, the 3RP, to improve the management of PTSD and lower respiratory symptoms in WTC workers (see preliminary data). The 3RP is an 8-session group-based program that seeks to promote the physiological, emotional, cognitive and behavioral effects of the relaxation response.The 3RP program focuses on 3 major areas to decrease stress and build resiliency: 1) eliciting the relaxation response via sustained mental focus with an attitude of open receptive awareness; 2) promoting stress awareness and decreasing reactivity, which involves identification of the 5 components of one's stress response (thoughts, emotions, physical reactions, behaviors, and relationship changes) and learning skills (e.g., cognitive restructuring) to change these components; and 3) increasing use of adaptive strategies by focusing on skills to promote positive growth and self-efficacy in response to stress. However, this intervention was not specifically developed for WTC workers with asthma and thus, does not address misperception of symptoms or disease SMB.

02

Conditions studied

  • Asthma
  • PTSD

Browse trials for

Keywords

  • World Trade Center
  • Cognitive Processing Therapy
  • Asthma
  • Intervention
  • Pilot Randomized Control Trial
03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 361 is above the median of 83 across 2,752 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Icahn School of Medicine at Mount Sinai is the lead sponsor of 764 studies on the registry; 181 are open to participants now.

Of its 121 completed or terminated interventional studies of FDA-regulated products, 82 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Pilot inclusion criteria:
  • Diagnosed with PTSD based on SCID or PCL-5
  • Poorly controlled asthma based on ACQ score ≥1.5; and
  • Completion of observational study 12-month visit.

Exclusion criteria

Exclusion Criteria:

  • Active Suicidal Ideation
  • Co-existence of COPD or other chronic respiratory illnesses
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
361 participants (actual)

Study arms

  • Experimental
    Cognitive Processing Therapy and Targeted Asthma Education

    Intervention group - Cognitive Processing Therapy and Targeted Asthma Education

    Behavioral: Cognitive Processing Therapy · Behavioral: Targeted Asthma Education

  • Active comparator
    Psychotherapy and General Asthma Education

    Control group - Psychotherapy and General Asthma Education

    Behavioral: Psychotherapy · Behavioral: General Asthma Education

Interventions

  • BehavioralCognitive Processing Therapy

    Integrated CPT. CPT is based on a social cognitive theory of PTSD that focuses on how the traumatic event is construed and coped with by a person who is trying to regain a sense of mastery and control in his or her life. The asthma components that will be integrated into the intervention include psychoeducation about asthma, barriers to asthma self-care, asthma medication education, inhaler technique, and asthma self-management behaviors.

    Also known as: CPT

  • BehavioralPsychotherapy

    The Study Interventionist will conduct generalized supportive psychotherapy with the participants to provide emotional support for both PTSD and general education for asthma.

  • BehavioralTargeted Asthma Education

    The manualized 10-session program of asthma self-management

    Also known as: Asthma Education

  • BehavioralGeneral Asthma Education

    A 10-session program of similar time

    Also known as: Asthma Education

06

What researchers measure

Primary outcomes

  1. PTSD Checklist for DSM-5 (PCL-5)

    The PTSD Checklist for DSM-5 (PCL-5), is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. The PCL-5 has a variety of purposes, including monitoring symptom change during and after treatment, screening individuals for PTSD, and making a provisional PTSD diagnosis. Full range from 0-80, higher score indicates more symptoms.

    Time frame: Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months

Secondary outcomes

  1. Asthma Control Questionnaire (ACQ)

    The ACQ assess asthma beliefs about asthma control. The ACQ is a 7-item instrument, full scale from 0-6, higher score indicates more impairment.

    Time frame: Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months

  2. Asthma Quality of Life Questionnaire (AQLQ)

    The AQLQ assess asthma beliefs about asthma quality of life. The AQLQ is a 32-item instrument, full scale from 1-7, higher score indicates better health outcomes

    Time frame: Baseline, 1 week post-intervention, 3 months post-intervention

  3. Medication Adherence Report Scale (MARS)

    The MARS assess asthma beliefs about asthma medication adherence. The MARS is a 10-item instrument, full range from 0-10, higher score indicates higher likelihood of medication adherence.

    Time frame: Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months

  4. Illness Perception Questionnaire (IPQ)

    The IPQ assess asthma beliefs about illness perception. The IPQ is an 80-item instrument, total scale from 0-80, with higher score indicating higher perception of effects on illness.

    Time frame: Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months

  5. Beliefs About Medicines Questionnaire (BMQ)

    Beliefs About Medicines Questionnaire (BMQ), a 10-item validated tool assessing medication necessity and concerns. The BMQ consists of two five-item scales assessing patients' beliefs about the necessity of medication and their concerns about taking it. Each item scored on a five-point Likert scale, ranging from 1 = strongly disagree to 5 = strongly agree. Total subscale scores for the Necessity and Concerns Scales range from 5 to 25. Higher scores indicate stronger beliefs.

    Time frame: Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months

  6. Patient Health Questionnaire-9 (PHQ-9) Depression Severity

    As a severity measure, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day). Total scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively.

    Time frame: Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months

  7. Generalized Anxiety Disorder-7

    The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. When used as a screening tool, further evaluation is recommended when the score is 10 or greater. Full scale from 0-21, with higher score indicating poorer health outcomes.

    Time frame: Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneCognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma Education
Started1919
Completed1919
Not completed00

Outcome measures

PrimaryPTSD Checklist for DSM-5 (PCL-5)

The PTSD Checklist for DSM-5 (PCL-5), is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. The PCL-5 has a variety of purposes, including monitoring symptom change during and after treatment, screening individuals for PTSD, and making a provisional PTSD diagnosis. Full range from 0-80, higher score indicates more symptoms.

Time frame:
Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months
Reported as:
Mean · score on a scale
PTSD Checklist for DSM-5 (PCL-5)
score on a scaleCognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma Education
Pilot Baseline Pre-Intervention39.2 ± 10.336.4 ± 9.6
1 Week Post-Intervention32.9 ± 14.734.3 ± 11.3
3 Months Post-Intervention29.8 ± 17.430.9 ± 9.1
SecondaryAsthma Control Questionnaire (ACQ)

The ACQ assess asthma beliefs about asthma control. The ACQ is a 7-item instrument, full scale from 0-6, higher score indicates more impairment.

Time frame:
Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months
Reported as:
Mean · score on a scale
Asthma Control Questionnaire (ACQ)
score on a scaleCognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma Education
Pilot Baseline Pre-Intervention2.1 ± 1.12.1 ± 0.4
1 Week Post-Intervention1.7 ± 1.02.0 ± 2.1
3 Months Post-Intervention1.9 ± 1.52.1 ± 0.9
SecondaryAsthma Quality of Life Questionnaire (AQLQ)

The AQLQ assess asthma beliefs about asthma quality of life. The AQLQ is a 32-item instrument, full scale from 1-7, higher score indicates better health outcomes

Time frame:
Baseline, 1 week post-intervention, 3 months post-intervention
Reported as:
Mean · score on a scale
Asthma Quality of Life Questionnaire (AQLQ)
score on a scaleCognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma Education
Pilot Baseline Pre-Intervention3.7 ± 1.13.7 ± 0.8
1 Week Post-Intervention4.3 ± 1.23.9 ± 1.0
3 Months Post-Intervention4.4 ± 1.63.8 ± 1.0
SecondaryMedication Adherence Report Scale (MARS)

The MARS assess asthma beliefs about asthma medication adherence. The MARS is a 10-item instrument, full range from 0-10, higher score indicates higher likelihood of medication adherence.

Time frame:
Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months
Reported as:
Mean · score on a scale
Medication Adherence Report Scale (MARS)
score on a scaleCognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma Education
Pilot Baseline Pre-Intervention4.4 ± 0.84.5 ± 0.7
1 Week Post-Intervention4.5 ± 0.64.5 ± 1.1
3 Months Post-Intervention4.6 ± 0.64.5 ± 0.8
SecondaryIllness Perception Questionnaire (IPQ)

The IPQ assess asthma beliefs about illness perception. The IPQ is an 80-item instrument, total scale from 0-80, with higher score indicating higher perception of effects on illness.

Time frame:
Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months
Reported as:
Mean · score on a scale
Illness Perception Questionnaire (IPQ)
score on a scaleCognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma Education
Pilot Baseline Pre-Intervention47.0 ± 14.346.8 ± 12.3
1 Week Post-Intervention41.4 ± 10.344.0 ± 12.3
3 Months Post-Intervention42.7 ± 13.144.6 ± 12.9
SecondaryBeliefs About Medicines Questionnaire (BMQ)

Beliefs About Medicines Questionnaire (BMQ), a 10-item validated tool assessing medication necessity and concerns. The BMQ consists of two five-item scales assessing patients' beliefs about the necessity of medication and their concerns about taking it. Each item scored on a five-point Likert scale, ranging from 1 = strongly disagree to 5 = strongly agree. Total subscale scores for the Necessity and Concerns Scales range from 5 to 25. Higher scores indicate stronger beliefs.

Time frame:
Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months
Reported as:
Mean · score on a scale
Beliefs About Medicines Questionnaire (BMQ)
score on a scaleCognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma Education
Pilot Baseline Pre-Intervention Necessity Score20.1 ± 2.819.5 ± 3.2
1 Week Post-Intervention Necessity Score20.7 ± 1.819.4 ± 4.1
3 Months Post-Intervention Necessity Score19.5 ± 3.518.8 ± 3.7
Pilot Baseline Pre-Intervention Concerns Score16.3 ± 2.717.2 ± 4.0
1 Week Post-Intervention Concerns Score16.0 ± 3.716.9 ± 4.4
3 Months Post-Intervention Concerns Score17.1 ± 4.616.0 ± 4.3
SecondaryPatient Health Questionnaire-9 (PHQ-9) Depression Severity

As a severity measure, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day). Total scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively.

Time frame:
Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months
Reported as:
Mean · score on a scale
Patient Health Questionnaire-9 (PHQ-9) Depression Severity
score on a scaleCognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma Education
Pilot Baseline Pre-Intervention12.9 ± 5.410.9 ± 4.9
1 Week Post-Intervention9.7 ± 4.610.4 ± 6.4
3 Months Post-Intervention10.1 ± 7.59.7 ± 5.8
SecondaryGeneralized Anxiety Disorder-7

The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. When used as a screening tool, further evaluation is recommended when the score is 10 or greater. Full scale from 0-21, with higher score indicating poorer health outcomes.

Time frame:
Baseline; 1 week post-intervention, up to 11 weeks; 3 months post-intervention, up to 5.5 months
Reported as:
Mean · score on a scale
Generalized Anxiety Disorder-7
score on a scaleCognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma Education
Pilot Baseline Pre-Intervention11.1 ± 5.19.4 ± 4.6
1 Week Post-Intervention10.1 ± 5.68.9 ± 5.7
3 Months Post-Intervention9.3 ± 7.88.1 ± 5.2

Adverse events

Collected over 3 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cognitive Processing Therapy and Targeted Asthma Education0/19 (0%)0/19 (0%)0/19 (0%)
Psychotherapy and General Asthma Education0/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

10 participants did not have their baseline demographic info because they were added later on in the pilot study

Age, Continuous
Age, Continuous(years)Cognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma EducationTotal
Mean57.3 ± 7.751.9 ± 8.354.2 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Cognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma EducationTotal
Female71017
Male5611
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma EducationTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American527
White or Caucasian347
More than one race000
Unknown or Not Reported or Other224
Hispanic or Latino2810
Education
Education(Participants)Cognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma EducationTotal
8th grade or less000
Some high school022
High school or GED235
1 to 3 years of college7815
4-year college graduate213
Higher degree022
Missing information101
Monthly income
Monthly income(Participants)Cognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma EducationTotal
Less than $30006814
More than $30006713
Missing Information011
Marital status
Marital status(Participants)Cognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma EducationTotal
Unmarried9514
Married31114
Language
Language(Participants)Cognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma EducationTotal
Mostly English111021
Mostly Spanish145
About the same022
Smoking status
Smoking status(Participants)Cognitive Processing Therapy and Targeted Asthma EducationPsychotherapy and General Asthma EducationTotal
Current/former smoker437
Never smoker61218
Missing Information213

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
09

References and documents

Publications

  • Wisnivesky JP, Becker JH, Ankam J, Markowitz SB, Doernberg M, Dickens B, Busse P, Crowley L, Federman A, Katz C, Weiss JJ, Gonzalez A. The Relationship Between Post-Traumatic Stress Disorder and Self-Management Behaviors in World Trade Center Workers with Asthma. J Allergy Clin Immunol Pract. 2022 Jan;10(1):242-249. doi: 10.1016/j.jaip.2021.08.035. Epub 2021 Sep 14. PubMed 34534721 ↗
  • Wisnivesky JP, Markowitz SB, James S, Stone K, Dickens B, Busse P, Crowley L, Federman A, Katz C, Gonzalez A. Comorbid posttraumatic stress disorder and major depressive disorder are associated with asthma morbidity among World Trade Center workers. Ann Allergy Asthma Immunol. 2021 Mar;126(3):278-283. doi: 10.1016/j.anai.2020.10.007. Epub 2020 Oct 22. PubMed 33098982 ↗
  • Wisnivesky JP, Agrawal N, Ankam J, Gonzalez A, Busse P, Lin J, Federman A, Feldman J, Weiss JJ, Markowitz SB. World Trade Center workers with asthma and post-traumatic stress disorder perceive airflow limitation more accurately. Ann Allergy Asthma Immunol. 2024 Jan;132(1):62-68. doi: 10.1016/j.anai.2023.08.005. Epub 2023 Aug 12. PubMed 37580015 ↗

Study documents

  • Protocol and statistical analysis plan · Jul 25, 2016
  • Informed consent form · Sep 21, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04552301
Lead sponsor
Icahn School of Medicine at Mount Sinai
Responsible party
Juan Wisnivesky (Chief of Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Sep 17, 2020
Start date
Aug 18, 2020
Primary completion
Jun 1, 2022
Completion
Jun 1, 2022
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Juan P Wisnivesky, MD, DrPH
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion